Keytruda Prolongs Life as First Line Treatment for Advanced Head & Neck Cancer

The best management for any patient with cancer is receiving the most innovative cancer drugs in advanced stages of development. There, the hope and chances to live longer go far beyond the standard protocols:

Keytruda and combination of Keytruda+platinum+5-FU as new first-line standards of care for recurrent or metastatic head and neck squamous cell carcinoma.

About KEYNOTE-048 trial

The phase III KEYNOTE-048 trial examined the efficacy of Keytruda alone, Keytruda + fluorouracil (5-FU) + cisplatin/carboplatin, or the standard of care which is Erbitux + 5-FU + cisplatin or carboplatin (also called the “EXTREME” protocol) as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma. 882 patients with locally incurable recurrent or metastatic head and neck cancer who had no prior systemic therapy in the recurrent or metastatic setting were enrolled.

At the 2019 ASCO Annual Meeting, the biggest oncology congress, the investigators presented the protocol-specified final results of the trial:

NOTE! “CPS” is a type of PD-L1 assessment score and the higher the score, the higher the PD-L1.

In the CPS ≥ 20 population (Highly positive PD-L1)

In the CPS ≥ 1 population (moderately positive PD-L1)

TRIAL•IN Pharma offers a unique, personalized search for patients with metastatic cancer and malignant brain tumors, which reveals advanced and innovative cancer treatments worldwide and helps to achieve them.

For free service assessment to our service, dial 24/7

+44.2082.426.039 or contact us through our website

Do not give up on life!

Learn more

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics